Thermo Fisher to manufacture Inovio's COVID-19 vaccine

By The Science Advisory Board staff writers

September 8, 2020 -- Thermo Fisher Scientific has signed a letter of intent to manufacture Inovio's DNA COVID-19 vaccine candidate, INO-4800.

Thermo Fisher is one of several contract development and manufacturing organizations that Inovio has tapped as part of a global manufacturing consortium to enable Inovio to potentially scale commercial production of INO-4800. Inovio plans to have 100 million doses of the vaccine manufactured in 2021, subject to regulatory approval.

Thermo Fisher will manufacture INO-4800 drug substance and perform fill/finish of the drug product at its commercial facilities in the U.S. At peak capacity, Thermo Fisher could produce at least 100 million doses of the candidate annually.

Existing partners of the global consortium include Richter-Helm BioLogics and Ology Biosciences. Inovio is in discussion with additional manufacturers to join the consortium. The company believes that having multiple manufacturers involved in the production of INO-4800 will support the timely, cost-effective, and scalable production of the DNA-based vaccine.

INO-4800 is a thermo-stable production with a shelf-life of greater than 5 years. The product also does not need to be frozen during transport. The vaccine is administered via Inovio's proprietary Cellectra smart delivery device, which delivers the vaccine locally into the skin.

Sharing is caring: Why COVID-19 vaccine manufacturers must collaborate
Sharing knowledge between competitors will be key for establishing the manufacturing capacity needed to produce billions of COVID-19 vaccines in coming...
Inovio reports long-term positive results for COVID-19 vaccine
Inovio released results of a nonhuman primate study for its COVID-19 DNA vaccine, INO-4800. The vaccine protected the animals 13 weeks after vaccinations...
Inovio vaccine proves potent against SARS-CoV-2 in preclinical trials
Inovio announced that preclinical data for its INO-4800 vaccine candidate were published in Nature Communications on May 20. The results suggesting...
Inovio expands manufacturing for COVID-19 vaccine
Inovio has partnered with German contract manufacturer Richter-Helm BioLogics to produce large-scale quantities of Inovio's investigational DNA vaccine.
DOD grant accelerates SARS-CoV-2 vaccine manufacturing
The U.S. Department of Defense (DOD) has awarded Ology Bioservices and Inovio Pharmaceuticals an $11.9 million contract to rapidly manufacture DNA...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter